A Phase 1 interventional study of Test: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG in Type 2 Diabetes Mellitus, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-03.
Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Diabetes Mellitus, Type 2 by Chong Kun Dang Pharmaceutical — 3 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Chong Kun Dang Pharmaceutical.
Among the 64 studies in Diabetes Mellitus, Type 2 by Chong Kun Dang Pharmaceutical, this one is the 13th largest by enrollment of the 62 interventional ones that give a count, is one of 8 that started in 2024, is one of 53 in phase 1, and was the 54th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 64 studies in Diabetes Mellitus, Type 2 by Chong Kun Dang Pharmaceutical are open now, in 1 country. Recruiting first, the newest first:
Chong Kun Dang Pharmaceutical · Sites in Korea, Republic of
Ages 19+
Chong Kun Dang Pharmaceutical · Sites in Korea, Republic of
Ages 19+
Chong Kun Dang Pharmaceutical
Ages 19–54 · Healthy volunteers
By country, each count listing its studies:
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 19 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 30 across the 62 interventional studies, 6,114 across the 2 observational. Of the 45 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.
1 of the studies in Diabetes Mellitus, Type 2 by Chong Kun Dang Pharmaceutical that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07365358Chong Kun Dang PharmaceuticalEvaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 64 studies in Diabetes Mellitus, Type 2 by Chong Kun Dang Pharmaceutical, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Randomized, open-label, single oral dosing, two-sequence, and two-period crossover study to evaluate the pharmacokinetics and safety between the administration of CKD-383 and the co-administration of CKD-501, D745, and D150 for healthy subjects in fed state
Participants were randomly assigned in a 1:1 ratio. The patients are prescribed oral administration of the appropriate IP(2 or 4 tablets in single dose: actual medication)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Phase 1: CKD-501 1 tablet, D745 1 tablet, D150 2 tablets(Reference) * Phase 2: CKD-383 2 tablets(Test)
Drug: Test: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG
* Phase 1: CKD-383 2 tablets(Test) * Phase 2: CKD-501 1 tablet, D745 1 tablet, D150 2 tablets(Reference)
Drug: Test: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG
At around 8 a.m., take Test drug or Reference drug 1,2,3(oral) with 200 mL of water at room temperature.
Also known as: Test: CKD-383, Reference1: CKD-501, Reference2: D745, Reference3: D150
AUCt of Lobeglitazone, Empagliflozin, Metformin
Pharmacokinetic characterization
Time frame: 0 hour ~ 48 hour after drug administration
Cmax of Lobeglitazone, Empagliflozin, Metformin
Pharmacokinetic characterization
Time frame: 0 hour ~ 48 hour after drug administration
AUC∞ of Lobeglitazone, Empagliflozin, Metformin
Pharmacokinetic characterization
Time frame: 0 hour ~ 48 hour after drug administration
Tmax of Lobeglitazone, Empagliflozin, Metformin
Pharmacokinetic characterization
Time frame: 0 hour ~ 48 hour after drug administration
T1/2 of Lobeglitazone, Empagliflozin, Metformin
Pharmacokinetic characterization
Time frame: 0 hour ~ 48 hour after drug administration
CL/F of Lobeglitazone, Empagliflozin, Metformin
Pharmacokinetic characterization
Time frame: 0 hour ~ 48 hour after drug administration
Vd/F of Lobeglitazone, Empagliflozin, Metformin
Pharmacokinetic characterization
Time frame: 0 hour ~ 48 hour after drug administration
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2024 to primary completion in Apr 2024, 0 months.
Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 0 months is below that.
Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chong Kun Dang Pharmaceutical →